Global Diagnosis and Treatment of Sexually Transmitted Infections Market 2023-2029

Sexually transmitted infections (STIs) are also known as sexually transmitted diseases, or STDs. STIs are usually transmitted through vaginal, oral, or anal sex. More than 30 different bacteria, viruses and parasites are known to be transmitted through sexual contact. Some STIs can also be transmitted from mother to child during pregnancy, childbirth and breastfeeding. In addition to the direct effects of the infection itself, sexually transmitted infections can have serious consequences. STIs like herpes, gonorrhea and syphilis can increase the risk of HIV acquisition. Mother-to-child transmission of STIs can lead to stillbirth, neonatal death, low birth weight and preterm birth, sepsis, neonatal conjunctivitis and congenital malformations. HPV infection causes cervical cancer and other cancers. According to the latest data, the market size of the global diagnosis and treatment of sexually transmitted infections sector is expected to rise by USD 21.0 billion with a CAGR of 4.6% by the end of 2029. The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global diagnosis and treatment of sexually transmitted infections market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the type, and region. The global market for diagnosis and treatment of sexually transmitted infections can be segmented by type: STIs diagnosis, STIs treatment. According to the research, the STIs treatment segment had the largest share in the global diagnosis and treatment of sexually transmitted infections market. Diagnosis and treatment of sexually transmitted infections market is further segmented by region: North America, Europe, Asia-Pacific, Rest of the World (RoW). In 2022, North America made up the largest share of revenue generated by the diagnosis and treatment of sexually transmitted infections market. The STIs diagnosis (by technology) market is further segmented into immunoassays, polymerase chain reaction (PCR), others. The latest analysis indicates that the immunoassays segment occupied the largest share of this market in 2022 and is expected to draw the highest demand in coming years. Furthermore, the STIs diagnosis (by location of testing) market has been categorized into location of testing, laboratory testing, point of care (PoC) testing. Globally, the laboratory testing segment made up the largest share of the diagnosis and treatment of sexually transmitted infections market. The STIs treatment (based on disease area) market is further divided into hepatitis B and C, HIV/AIDS, others. The hepatitis B and C segment was the largest contributor to the global diagnosis and treatment of sexually transmitted infections market in 2022. The STIs treatment (by drug class) market is further segmented into antibiotics, antiviral and antiretroviral, others. The latest analysis indicates that the antiviral and antiretroviral segment occupied the largest share of this market in 2022 and is expected to draw the highest demand in coming years. Market Segmentation By type: STIs diagnosis, STIs treatment By region: North America, Europe, Asia-Pacific, Rest of the World (RoW) The report explores the recent developments and profiles of key vendors in the Global Diagnosis and Treatment of Sexually Transmitted Infections Market, including Abbott Laboratories, AbbVie Inc., Agilent Technologies, Inc., Becton, Dickinson and Company, bioMerieux SA, Bio-rad Laboratories, Inc., Boehringer Ingelheim Corporation, Danaher Corporation, DiaSorin S.p.A., Esco Micro Pte. Ltd., F. Hoffmann-La Roche AG, Gen-Probe Incorporated (Hologic, Inc.), Gilead Sciences, Inc., GSK plc, MedMira Holding AG, Merck & Co., Inc., Meridian Bioscience Inc., Novartis AG, OraSure Technologies, Inc., Pfizer Inc., Promega Corporation, Qiagen N.V., QuantuMDx Group Ltd., QuidelOrtho Corporation, Seegene, Inc., Sekisui Medical Co., Ltd., Siemens Healthineers AG, The Bristol-Myers Squibb Company (BMS), Thermo Fisher Scientific, Inc., Trinity Biotech Plc., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market. *REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES Scope of the Report • To analyze and forecast the market size of the global diagnosis and treatment of sexually transmitted infections market. • To classify and forecast the global diagnosis and treatment of sexually transmitted infections market based on type, region. • To identify drivers and challenges for the global diagnosis and treatment of sexually transmitted infections market. • To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global diagnosis and treatment of sexually transmitted infections market. • To identify and analyze the profile of leading players operating in the global diagnosis and treatment of sexually transmitted infections market. Why Choose This Report • Gain a reliable outlook of the global diagnosis and treatment of sexually transmitted infections market forecasts from 2023 to 2029 across scenarios. • Identify growth segments for investment. • Stay ahead of competitors through company profiles and market data. • The market estimate for ease of analysis across scenarios in Excel format. • Strategy consulting and research support for three months. • Print authentication provided for the single-user license.